Health Technology · Pharmaceuticals: Major · NSE: MANKIND · data 2026-10-09
Mankind Pharma Ltd.
Health check: Average (6.3/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹2,368.5
Market cap
₹99,065 cr
P/E
47.9
P/B
—
ROE
12.5%
ROCE
12.7%
Debt / equity
0.39
Dividend yield
0.04%
1-year return
-3.3%
52-week high
₹2,642
52-week low
₹1,909.7
Operating margin
19.9%
Growth
| Revenue (last 12 months) | ₹14,738 cr |
| Net profit (last 12 months) | ₹2,043 cr |
| Sales growth, 3 years (yearly) | 17.8% |
| Profit growth, 3 years (yearly) | 14.3% |
Similar companies
Zydus Lifesciences Limited (ZYDUSLIFE) · Laurus Labs Ltd. (LAURUSLABS) · Dr. Reddy's Laboratories Ltd. (DRREDDY) · Alkem Laboratories Ltd. (ALKEM) · Glenmark Pharmaceuticals Limited (GLENMARK)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open MANKIND in NSE Scanner →